Novartis(US:NVS) Zhi Tong Cai Jing·2025-11-20 08:01Core Insights - Novartis (NVS.US) expects its sales to grow by 5% to 6% by 2030, adjusted for currency, driven by higher revenue expectations for its cancer drugs Kisqali and Scemblix [1] Sales Projections - The peak sales forecast for Kisqali, used to treat a common type of breast cancer, has been raised from $8 billion to at least $10 billion [1] - For the leukemia drug Scemblix, the peak sales forecast is now at least $4 billion, up from a previous estimate of at least $3 billion [1] - The company indicates that its eight most promising approved drugs each have potential peak sales ranging from $3 billion to $10 billion [1] Strategic Acquisitions - Recently, the company acquired Avidity Biosciences for $12 billion to enhance its pipeline of treatments for muscle diseases, part of a broader strategy to offset declining sales from existing products, including its heart failure drug Entresto [1] - This acquisition is expected to increase the company's annual sales growth forecast for 2024 to 2029 to 6%, up from a prior estimate of 5% [1]